Monoclonal antibody-based immunotherapy for multiple myeloma

Ivetta Danylesko, Katia Beider, Avichai Shimoni, Arnon Nagler*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Multiple myeloma (MM) is a life-threatening hematological malignancy. High-dose chemotherapy followed by autologous stem cell transplantation is a relatively effective treatment, but disease recurrence remains a major obstacle. Allogeneic transplantation may result in durable responses and cure due to antitumor immunity mediated by donor lymphocytes. However, morbidity and mortality related to graft-versus-host disease remain a challenge. Recent advances in understanding the interaction between the immune system of the patient and the malignant cells are influencing the design of clinically more efficient study protocols for MM. This review will focus on MM antigens and their specific antibodies. These monoclonal antibodies are an attractive therapeutic tool for MM humoral immunotherapy, with most promising preclinical results.

Original languageEnglish
Pages (from-to)919-938
Number of pages20
Issue number9
StatePublished - Sep 2012


  • humoral immunity
  • immunotherapy
  • molecular targets
  • monoclonal antibodies
  • multiple myeloma


Dive into the research topics of 'Monoclonal antibody-based immunotherapy for multiple myeloma'. Together they form a unique fingerprint.

Cite this